[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"suicidal-ideas\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:suicidal-ideas":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,49,83,94,129,156],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100053248","neural-derived-plasma-exosomal-micrornas-as-promising-novel-biomarkers-for-suicidality-and-treatment-outcome-in-adolescents-100053248",false,"NCT05437588","Neural-Derived Plasma Exosomal MicroRNAs As Promising Novel Biomarkers for Suicidality and Treatment Outcome in Adolescents","Inclusion Criteria:\n\nAll participants:\n\n1. Physically healthy\n2. willing and able to provide informed consent (if under 18 also parent or guardian consent)\n\nMDD participants:\n\n1. A definite diagnosis of DSM-5\n2. a Children's Depression Rating Scale-Revised (CDRS-R) score \\>=30. Suicidal ideation participants: Columbia Suicide Severity Rating Scale (C-SSRS) score \\>=4 rated over the last two weeks.\n\nSuicide attempt group:\n\n1\\. Participants will have had an attempt in the previous two weeks that is serious enough to require medical attention and shows evidence of at least a medium level of intent on the Suicide Intent Scale.\n\nNon-psychiatric controls:\n\n1\\. No history of any major mental illness (excluding specific phobia) or substance use disorder.\n\nExclusion Criteria:\n\n* Exclusion criteria:\n\n  1. Pregnancy or lactation\n  2. post-partum state (being within 2 months of delivery or miscarriage);\n  3. homicide risk as determined by clinical interview\n  4. any of the following DSM-V diagnoses or categories: a) a lifetime history of psychotic disorder; b) alcohol or drug use disorder (except nicotine\u002Fcaffeine) within the last month; the use of any hallucinogen (except cannabis), including phencyclidine in the last month; c) bipolar disorder; d) pervasive developmental disorder; e) cognitive disorder; f) DSM-5 paranoid, schizoid, or schizotypal personality disorders (PDs) (participants with other PDs will be allowed as long as MDD criteria are met); g) anorexia nervosa.\n  5. recent myocardial infarction or unstable angina, active neoplasm in the past 6 months, immunosuppressive or corticosteroid therapy within the last month, chemotherapy, and head injury or loss of consciousness in the past 6 months\n  6. use of hallucinogens (except for cannabis), methamphetamine, or cocaine in the last 2 weeks.",true,"ALL","10 Years","24 Years",{"count":20,"type":21},240,"ESTIMATED","INTERVENTIONAL",[24],"NA","This study is dedicated to help identify biomarkers for depression and suicide. The purpose of the study is to better understand these links to improve medical and psychiatric care in the future. This research is also to test the effects of standard treatment of depression on improvement in depressive and suicidal behavior and on biomarkers (e.g. miRNA) for these disorders.",[27,28,29,30,31,32,33,34,35],"Major Depressive Disorder","Suicidal Ideas","Suicide, Attempted","MDD","Depression","Depression, Teen","Depression and Suicide","Depression in Adolescence","Suicide","RECRUITING","2026-07-10",{"date":39,"type":40},"2026-07-13","ACTUAL",{"date":42,"type":40},"2022-10-01",{"date":44,"type":21},"2027-06-30",{"name":46,"class":47},"University of Alabama at Birmingham","OTHER",2,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":55,"eligibilityCriteria":56,"healthyVolunteers":15,"sex":16,"minAge":57,"maxAge":58,"enrollmentInfo":59,"targetDuration":4,"studyType":22,"phases":61,"briefSummary":62,"conditions":63,"keywords":66,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":82},"100586887","exploratory-analysis-of-interpersonal-and-intrapersonal-psychological-processes-implied-in-risk-taking-and-suicidal-behaviors-in-adult-and-adolescent-at-risk-100586887","NCT06921226","Exploratory Analysis of Interpersonal and Intrapersonal Psychological Processes Implied in Risk-taking and Suicidal Behaviors, in Adult and Adolescent At-risk","Intra-personal and Interpersonal Psychological Processes Involved in Risk-taking and Suicidal Behaviors Among Vulnerable Adolescents and Adults","RISKY","Inclusion Criteria:\n\n* Age 12-65 years\n* Adolescent population considered as at risk in mental health : admitted to the peadiatric department (CHMS).\n\nor - Adult population : user of the Espoir73 association (an association for adults with a mental health problem) or users of SM@RT (CHS, a psycho-social rehabilitation center for adults with a mental illness).\n\nExclusion Criteria:\n\n\\- No suicidal ideation or behaviors (none \" Yes \" response at the 6 questions of the C-SSRS screen version).","12 Years","65 Years",{"count":60,"type":21},1400,[24],"In a recent report, Santé Publique France (2023), reported that 4.2% of 18-85 year-olds had thought about suicide in the last 12 months, and 6.8% had attempted suicide in their lifetime and 0.5% in the last year. Even more recently, the DREES (Direction de la recherche, des études, de l'évaluation et des statistiques auprès des Ministères Sociaux) published a report on May 16, 2024, showing a sharp rise in hospitalization rates for self-inflicted acts among female patients aged between 10 and 24, with a peak around age 15. Two-thirds of these hospitalizations for self-inflicted injuries are related to deliberate drug intoxication. Depression, bipolar disorders and schizophrenia spectrum disorders (among other psychological disorders) are known risk factors for suicide, which is the leading cause of death in this clinical context. In addition to these formalized psychopathological elements, risk behaviors underpinned by psychological processes common to suicide attempts are suspected and need to be studied in depth.\n\nResearch into psychiatry and the psychopathology of suicide has identified a number of risk and protective factors. These psychological determinants - or processes - act alongside other key factors such as the environment and social ties. Life contexts can have an impact on health, and more specifically on the psychopathology of individuals, through disturbances of a biological, psychological and social nature. It is important to be able to describe what processes are at work and how they explain the development and maintenance of behaviours that put one's life and health at risk. This is part of a preventive approach to mental health. We suggest that the study of psychological processes such as suicidal ruminations, impulsivity and interpersonal needs (e.g. the interpersonal theory of suicide) is necessary to understand their involvement in risk-taking and suicidal behavior. To our knowledge, few studies of this type are underway in France, particularly with vulnerable clinical populations (adolescents\u002Fadults). The inclusion of a process-centered approach (Kinderman, 2015), in a transdiagnostic and preventive way, constitutes an innovative approach.",[28,64,65],"Suicidal Ideation","Risk-taking",[67,68,69,70,71,72],"Risk-taking behaviors","Impulsivity","Interpersonal needs","Suicidal ruminations","Suicidal behaviors","BART","2026-06-09",{"date":75,"type":40},"2026-06-10",{"date":77,"type":40},"2025-06-26",{"date":79,"type":21},"2027-06-26",{"name":81,"class":47},"Centre Hospitalier Metropole Savoie",3,{"id":84,"slug":4,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":85,"targetDuration":4,"studyType":22,"phases":86,"briefSummary":25,"conditions":87,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":91,"completionDateStruct":92,"leadSponsor":93,"locationsCount":48},"100472876",{"count":20,"type":21},[24],[27,28,29,30,31,32,33,34,35],"2025-07-08",{"date":90,"type":40},"2025-07-11",{"date":42,"type":40},{"date":44,"type":21},{"name":46,"class":47},{"id":95,"slug":96,"hasResults":11,"nctId":97,"briefTitle":98,"officialTitle":99,"acronym":100,"eligibilityCriteria":101,"healthyVolunteers":15,"sex":16,"minAge":102,"maxAge":4,"enrollmentInfo":103,"targetDuration":4,"studyType":22,"phases":105,"briefSummary":106,"conditions":107,"keywords":112,"overallStatus":118,"whyStopped":4,"lastUpdateSubmitDate":119,"lastUpdatePostDateStruct":120,"startDateStruct":122,"completionDateStruct":124,"leadSponsor":126,"locationsCount":128},"100593929","couple-based-crisis-safety-planning-100593929","NCT07012824","Couple-Based Crisis Safety Planning","Couple-Based Crisis Response Planning for Veterans","CRP-C","Inclusion Criteria:\n\n* (At least) One participant from the couple must have Veteran status\n* Currently resides in Georgia\n* English speaking\n* The Veteran must own a smartphone\n* Veteran must have experienced crisis symptoms in the past three months. At least 1 symptom of entrapment, and at least 1 symptom from 2 of the associated disturbance categories \\[i.e. affective disturbance, loss of cognitive control, hyperarousal, or social withdrawal\\]\n* Currently be in a committed relationship for at least one year\n* The Veteran must be able to present a copy of DD form 214 (Certificate of Release or Discharge from Active Duty issued by the U.S. Department of Defense)\n\nExclusion Criteria:\n\n* Non-English speaking\n* Under 18 years of age\n* Resides in a different state than Georgia\n* Either partner reports injury or fear resulting from intimate partner violence in the past three months.\n* Participants who meet study criteria for imminent suicide risk Depressive Symptom Index - Suicidality Subscale (Joiner et al., 2002), defined as a DSI- SS score of 7 or greater, or selecting \"3\" on items B \\[formulated plan\\] or D \\[constant urge to kill self (I. H. Stanley et al., 2021)","18 Years",{"count":104,"type":21},100,[24],"Suicide is a leading cause of death in Veterans. Suicide rates among Veterans have increased approximately 36% from 2001 to 2020. Veterans are at increased risk for suicide compared to non-Veterans, with the rate of suicide death being 57.3% higher for Veterans than non-Veterans. The present study will pilot test a virtual couple-based crisis response plan (CRP-C) for Veterans in order to reduce crisis symptoms and decrease suicide risk.",[28,64,108,109,110,111],"Crisis; Emotional","Suicide Attempts","Suicidal and Self-injurious Behaviour","Suicidal Impulses",[113,114,115,116,117],"Veteran safety","Suicide risk","Crisis safety plan","Suicide crisis","intervention","NOT_YET_RECRUITING","2025-06-08",{"date":121,"type":40},"2025-06-10",{"date":123,"type":21},"2025-06",{"date":125,"type":21},"2027-08",{"name":127,"class":47},"University of Georgia",1,{"id":130,"slug":131,"hasResults":11,"nctId":132,"briefTitle":133,"officialTitle":133,"acronym":4,"eligibilityCriteria":134,"healthyVolunteers":11,"sex":16,"minAge":57,"maxAge":135,"enrollmentInfo":136,"targetDuration":4,"studyType":22,"phases":138,"briefSummary":140,"conditions":141,"keywords":143,"overallStatus":118,"whyStopped":4,"lastUpdateSubmitDate":147,"lastUpdatePostDateStruct":148,"startDateStruct":150,"completionDateStruct":152,"leadSponsor":154,"locationsCount":4},"100589691","phase-3-evaluation-of-the-efficacy-and-safety-of-subcutaneous-ketamine-in-the-treatment-of-depressive-episode-with-suicidal-ideation-andor-behavior-in-adolescents-100589691","NCT06957704","Evaluation of the Efficacy and Safety of Subcutaneous Ketamine in the Treatment of Depressive Episode With Suicidal Ideation and\u002For Behavior in Adolescents","Inclusion Criteria:\n\n* Age between 12 and 19 years.\n* Diagnosis of Major Depressive Episode, unipolar, made through the Schedule for Affective Disorders and Schizophrenia for School-Age Children (K-SADS-PL) administered by experienced evaluators, using DSM-5 criteria.\n* Under usual treatment for Major Depressive Episode, including clinically indicated psychopharmacological treatment and\u002For psychosocial treatment at one of the two collaborating clinics (DICA and Conversas de Vida \u002F Unifesp).\n* Score ≥ 25 on the MADRS (Montgomery-Åsberg Depression Rating Scale).\n* Score ≥ 28 on the CDRS (Children Depression Rating Scale).\n* Score ≥ 2 on the Columbia Suicide Severity Rating Scale (C-SSRS).\n* History of suicide attempt or significant suicidal ideation or planning with a plan or intention requiring emergency evaluation in the last 30 days.\n\nExclusion Criteria:\n\n* Presence of the following psychiatric comorbidities: Autism Spectrum Disorder, Bipolar Disorder, Schizophrenia, Schizoaffective Disorder, or psychiatric disorder secondary to physical illness, and history of ketamine or other substance abuse or dependence in the last 6 months.\n* Presence of Intellectual Disability (assessed by IQ testing).\n* Presence of the following clinical comorbidities: history of myocardial infarction, congenital heart disease, decompensated cardiac arrhythmia, decompensated hypertension, porphyria, stroke, brain trauma with loss of consciousness, intracranial hypertension, hydrocephalus, central nervous system tumors, or central nervous system abnormalities.\n* Previous treatment for depression with esketamine.\n* Allergy to esketamine.\n* If female: pregnancy or breastfeeding.","19 Years",{"count":137,"type":21},60,[139],"PHASE3","Evaluate the efficacy and safety of subcutaneous ketamine added to usual treatment in the management of depressive episodes with suicidal ideation or behavior in adolescent patients, compared to usual treatment added to placebo (midazolam).",[142,28],"Depressive Disorder",[144,145,27,146],"Adolescent","Ketamine","Midazolam","2025-05-02",{"date":149,"type":40},"2025-05-04",{"date":151,"type":21},"2025-05",{"date":153,"type":21},"2028-04",{"name":155,"class":47},"Federal University of São Paulo",{"id":157,"slug":158,"hasResults":11,"nctId":159,"briefTitle":160,"officialTitle":161,"acronym":162,"eligibilityCriteria":163,"healthyVolunteers":11,"sex":16,"minAge":57,"maxAge":164,"enrollmentInfo":165,"targetDuration":4,"studyType":22,"phases":167,"briefSummary":168,"conditions":169,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":170,"lastUpdatePostDateStruct":171,"startDateStruct":173,"completionDateStruct":175,"leadSponsor":177,"locationsCount":128},"100544242","study-of-iv-ketamine-for-emergency-department-treatment-of-adolescent-suicidal-ideation-100544242","NCT06366334","Study of IV Ketamine for Emergency Department Treatment of Adolescent Suicidal Ideation","A Double Blinded, Randomized, Placebo Controlled, Parallel Arm Pilot Trial of Intravenous Ketamine for Emergency Department Treatment of Suicidal Ideation in a Pediatric Population.","KSI","Inclusion Criteria:\n\n1. Responds \"yes\" to Ask Suicide Screening Question (ASQ) #5 at triage, which asks; \"Are you having thoughts of killing yourself right now?\"\n2. Moderate to severe suicidal ideation, defined as score ≥ 3 on the first 5 questions of the Beck Scale for Suicidal Ideation (SSI5)\n3. Age 12 to 17 years, inclusive\n4. Medically clear (deemed fit for participation in the trial), as judged by the treating physician. Minimum criteria required to be deemed medically clear are: a) No evidence of serious physical injury requiring urgent intervention b) No evidence of acute ingestion requiring monitoring, blood tests, imaging or ECG or in the context of acute ingestion they have satisfied the requisite number of hours of post-ingestion monitoring with no further need for intervention.\n\nExclusion Criteria:\n\n1. Acute intoxication from any substance, including alcohol\n2. Previously enrolled in the current study or currently enrolled in another clinical trial\n3. History of intellectual disability or autism spectrum disorder by patient\u002Fparent report\n4. Active, or history of, psychosis or psychotic disorder\n5. History of non-psychiatric neurologic disorder (e.g., epilepsy)\n6. Any of the following contraindications to ketamine based on the drug monograph: a) Known allergy or hypersensitivity to ketamine by patient history b) History of cerebrovascular accident (stroke or aneurysm) c) History of elevated intracranial pressure or idiopathic intracranial hypertension d) Significant hypertension requiring daily medication e) Severe cardiac decompensation\n7. On an involuntary psychiatric hold\n8. Requires physical or chemical restraint\n9. History of violence while in hospital\n10. Pregnant or breastfeeding\n11. Received opioids in the 2-hours prior to study screening","17 Years",{"count":166,"type":21},20,[24],"Approximately 20% of Canadian adolescents experience thoughts of suicide, or suicidal ideation (SI), and suicide is the second leading cause of death among Canadians aged 15-19 years. The emergency department at CHEO sees approximately four patients per day with SI. Even though this is a medical emergency, there are no fast-acting treatments available.\n\nKetamine is a medication that is commonly used to safely sedate children who require painful procedures in the emergency department. For nearly ten years, intravenous ketamine has also been shown to rapidly reduce SI in adults. However, ketamine as a treatment for SI has never been studied in adolescents. The primary study objective is to pilot a clinical trial that investigates intravenous ketamine to emergently treat SI in adolescents.\n\nIf intravenous ketamine can relieve symptoms of SI for youth, this would have tremendous effects on patients and would dramatically change how physicians treat adolescent mental health emergencies. If ketamine is effective for several weeks, as it is in adults, it will help temporize patients until they receive more long-term psychiatric care. At the system level, it has the potential to reduce emergency visits and lengthy admissions. The investigators feel that the results of this study will be generalizable to pediatric centres across Canada and beyond.",[64,28],"2024-06-04",{"date":172,"type":40},"2024-06-05",{"date":174,"type":40},"2024-01-15",{"date":176,"type":21},"2024-06-28",{"name":178,"class":47},"Children's Hospital of Eastern Ontario"]